Charles Schwab Investment Management Inc Neoleukin Therapeutics, Inc. Transaction History

Charles Schwab Investment Management Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.92 - $2.25 $81,506 - $199,336	-88,594 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$9.23 - $13.12 $55,675 - $79,139	6,032 Added 7.31%	88,594 $818,000
Q1 2021 May 17, 2021	BUY	$11.26 - $15.78 $65,859 - $92,297	5,849 Added 7.62%	82,562 $1.02 Million
Q4 2020 Feb 16, 2021	SELL	$10.17 - $14.56 $1,494 - $2,140	-147 Reduced 0.19%	76,713 $1.08 Million
Q3 2020 Nov 13, 2020	BUY	$9.68 - $17.01 $28,081 - $49,346	2,901 Added 3.92%	76,860 $923,000
Q2 2020 Aug 14, 2020	BUY	$9.95 - $17.05 $596,024 - $1.02 Million	59,902 Added 426.14%	73,959 $1.23 Million
Q4 2019 Feb 07, 2020	BUY	$2.65 - $12.72 $37,251 - $178,805	14,057 New	14,057 $174,000

199K

Ticker NLTX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 42,579,900
Description
Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of vario...

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

Stay updated on Charles Schwab Investment Management Inc with notifications on news.